Disease / condition

Ametropia clinical trials

Free access to 40 studies·10+ countries·Updated daily10 recruiting
40
Total trials
10+
Countries
10+
Sponsors
10
Recruiting
By phase
N/A34
Early Phase 13
Not Applicable1
Phase 31
Phase 41
By status
Completed24
Recruiting10
Not yet recruit...3
Recruitment Com...1
Withdrawn1
Top countries
China10
United States of America7
Germany4
Canada4
Mexico4
Top sponsors
Coopervision, Inc.11
Contamac Ltd4
Johnson & Johnson ...4
Bausch & Lomb Inco...3
University of Wate...3
Recent trials
Latest clinical trials for Ametropia
NCT06400914Recruitment ...
Clinical Evaluation of Biomedics Monthly Sphere and Avaira Vitality Sphere
Coopervision, Inc.Mexico
NCT06295536Not yet recr...
Optimization of a Photoretinoscopy Method for Determining the Objective Refraction of Children
Essilor International
NCT05516082Recruiting
Clinical Evaluation of Two Daily Disposable Lenses in Sphere Design
Coopervision, Inc.Mexico
NCT05166902Completed
Evaluation of Monthly Replacement Lenses in Habitual Soft Contact Lens Wearers Who Report Frequent Digital Devise Use
Coopervision, Inc.Canada,United States of America
ChiCTR2100050448Recruiting
Untitled Trial
Wuhan Aier Hongshan Eye Hospit...China
ChiCTR2100047005Recruiting
Untitled Trial
The First Affiliated Hospital ...China
NCT04654455Completed
Prospective Study Evaluating Dry Eye in Patients Operated on for Ametropia by LASIK Surgery and Treated With REPADROP
Hospices Civils de LyonFrance
NCT04617080Recruiting
Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment Algorithm
Bausch & Lomb IncorporatedPhilippines
NCT04698174Recruiting
Safety and Efficacy of a New Transepithelial Photorefractive Keratectomy Treatment
Bausch & Lomb IncorporatedPhilippines
ChiCTR2000039272Recruiting
Untitled Trial
Huangshi Aier Eye HospitalChina
ChiCTR2000035982·Early Phase 1Not yet recr...
Untitled Trial
EENT Hospital of Fudan Univers...China
ChiCTR2000033554Completed
Untitled Trial
Eye Optometry Hospital Affilia...China
NCT04067141Completed
The Clinical Comparison of Somofilcon A 1 Day and Nelfilcon A Daily Disposable Contact Lenses
Coopervision, Inc.United Kingdom
NCT04067050Completed
A Clinical Study of the Comfilcon A Asphere Soft Contact Lens in Users of Digital Devices
Coopervision, Inc.United Kingdom
ChiCTR1900022049·Early Phase 1Recruiting
Untitled Trial
Hainan Ophthalmological Hospit...China
ChiCTR1900021237Recruiting
Untitled Trial
Hainan Ophthalmological Hospit...China
NCT03835221Completed
Performance of Toric Hydrogel Lenses Following A Refit With Toric Silicone Hydrogel Lenses for 1 Month
Coopervision, Inc.Mexico
NCT03835078Completed
Performance of Aspheric Hydrogel Lenses After a Refit With Sphere Silicone Hydrogel Lenses for 4 Weeks
Coopervision, Inc.Mexico
NCT03556579Completed
The Effects of Contact Lenses With Experimental Dye on Visual Function
Johnson & Johnson Vision Care,...United States of America
NCT03319212Completed
Clinical Characterization of Symptomatic Populations
Johnson & Johnson Vision Care,...Canada,United States of America
About this record

Access comprehensive clinical trial information for Ametropia through Pure Global AI's free database. This collection includes 40 clinical trials across multiple phases including N/A, Early Phase 1, Not Applicable. Currently, 10 trials are actively recruiting participants.

Research for Ametropia is being conducted in China, United States of America, Germany and 7+ other countries. Leading sponsors include Coopervision, Inc. and Contamac Ltd. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.

Pure Global AI provides free access to 40 clinical trials studying Ametropia, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.

The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.

Top research sponsors include Coopervision, Inc., Contamac Ltd, Johnson & Johnson Vision Care, Inc., among others.